Inclusion Criteria

- INCLUSION CRITERIA:

Patients must fulfill all of the following criteria to be eligible for study admission:

1. Age greater than 18 years.

2. Histologic or cytologic confirmation at National Cancer Institute (NCI) Laboratory of
Pathology, of recurrent or refractory, or advanced metastatic cancer of the
gastrointestinal tract, breast, Taxol (Trademark) naive breast cancer, small cell
lung, ovarian, prostate, head and neck, multiple myeloma, non-small cell lung cancer,
Taxol (Trademark) naive non-small cell lung cancer.

3. Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2.

4. Life expectancy of 3 months or greater.

5. Patient must have adequate hematologic, renal, hepatic, and metabolic functions as
defined: platelet count greater than 100,000 /mL, absolute granulocyte count (AGC)
greater than 1500/mL, serum creatinine less than 2.0 mg/dl (or if greater than 2.0, a
measured 24 hour creatinine clearance greater than 50 mL/min), serum glutamic
oxaloacetic transaminase (SGOT) 4 times institutional upper limit of normal,
bilirubin 2.0 mg/dl, prothrombin time (PT) less than 1.5 times institutional upper
limit of normal, partial thromboplastin time (PTT) less than 1.5 times institutional
upper limit of normal, calcium less than 5.3mEq/L, albumin greater than 2.0 g/dl.

6. Electrocardiogram (EKG) showing, at most, minor abnormalities that in the judgment of
the protocol chairman would not compromise the patient's ability to tolerate therapy.

7. Patients must be greater than 4 weeks from prior radiation or chemotherapy; greater
than 2 weeks from hormonal or immunotherapy; greater than 4 weeks from prior
experimental therapy; greater than 6 weeks from mitomycin; and greater than 8 weeks
from prior UCN01 treatment. Patients receiving dexamethasone as a pretreatment for
anaphylactic reactions to Taxol (Trademark) or the cremophor vehicle will not be
excluded from this study.

8. No serious intercurrent medical illness or serious infection that requires parenteral
antibiotics.

9. Measurable disease by radiographic means or physical examination.

10. Willingness to sign a written informed consent.

11. Patients must agree to an effective method of contraception for the study
(abstinence, hormonal or barrier method of birth control, or condom) for the study
and 30 days after completion of protocol.

EXCLUSION CRITERIA:

The following patient populations are not eligible for study:

1. Women of childbearing potential and potentially fertile men will be excluded unless
using an effective contraception (ie. a barrier intrauterine device (IUD), birth
control pill, or condom), during the treatment. Women who are pregnant or nursing
will also be excluded.

2. Patients with significant intercurrent disease.

3. Human Immunodeficiencey virus (HIV) seropositive patients. Note: There may be an
impact of CBT-1 on the pharmacokinetics of the drugs used in the therapy of HIV.

4. Ongoing serious infections that require parenteral antibiotics.

5. Patients with significant central nervous system (CNS) disease, including a history
of seizures within the last 3 months or psychiatric history which would impair the
ability to give informed consent or prevent compliance with protocol requirements.

6. Patients must not be eligible for surgery, or radiotherapy that is of known benefit
to them, in terms of extension of survival. Patients with tumors sensitive to
potentially curative chemotherapy must have failed such chemotherapy. Patients who
have received radiation therapy may participate in this study one week after the
conclusion of radiation therapy provided that the lesion being irradiated is not one
that is being used to assess the efficacy of CBT-1 plus Taxol.

7. History of significant coronary artery disease, cardiac arrhythmias requiring
treatment, or history of other cardiac disease that in the judgment of the
investigators, would compromise the patient's ability to tolerate the therapy.

8. Patients with active bleeding due to peptic ulcer disease.

9. History of anaphylactic reactions to paclitaxel or cremophor despite adequate
premedication.

10. Clinically significant bleeding disorders.

11. Patients with solid organ allografts.

12. Patients on daily gastric acid secretion inhibitors.